Health Equity & Access to Medicine

Regeneron strives to push the boundaries of science beyond the imaginable. Through innovative access strategies and initiatives that focus on affordability and support, we work to get our medicines to patients in need.

Our performance and progress

35+

product candidates in clinical development

Regeneron Logo

2.5M+

exomes sequenced by Regeneron Genetics Center® since it was founded in 2013

Regeneron Logo

$2.2B

in medicines donated through patient assistance programs

Based on 2023 year-end wholesale acquisition cost.

Regeneron Logo

>1M

eligible patients received support from our patient support programs

Regeneron patient assistance programs are limited to patients living in the United States and U.S. territories.

Regeneron Logo

>200

patient advocacy and professional societies engaged across 40 diseases to address unmet patient needs

1st

Zaire ebolavirus treatment approved by the FDA, and first to be prequalified by the World Health Organization

Pipeline innovation for patients

We follow the science to unexpected breakthroughs and diverse areas of study, including understudied diseases. Our pipeline is composed of primarily homegrown therapeutics, powered by our proprietary VelociSuite® technologies and informed by discoveries made in our Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.

 ""

Inclusive science

We continue to harness the diversity of our team to ensure we come up with the best ideas, bring underrepresented voices into our labs and create meaningful collaborations. Throughout the R&D process, we work to facilitate access to our clinical studies and strive for representation that reflects diverse patient populations.

Explore our current pipeline candidates in a variety of diseases.

Advancing African Ancestry Representation in Genomic Research and STEM Education

Driven to make a difference through the Together for CHANGE™ Initiative

Read more about the Together for CHANGE™ Initiative

Responsible pricing and access

We focus on removing barriers to access to healthcare so people can live their healthiest lives. This includes pricing our medicines with fairness and affordability in mind.

 A doctor talking to an elderly patient.

Patient support programs

We help make our products more accessible through our patient support programs. We also provide patient assistance programs designed to provide education and to increase access through insurance eligibility support, patient resources, financial assistance and access to free medicine.

Access to investigational medicines

Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval. Our Compassionate Use Policy gives certain U.S.-based patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials are available.

Patient assistance foundations

We donate to independent third-party charitable foundations, known as patient assistance foundations, which provide financial assistance to patients who might not otherwise be able to afford their medications.

Patient advocacy

We are deeply committed to understanding the patient community’s challenges and unmet needs. Through our shared, patient-centric approach, we elevate patient voices, improve disease awareness and support equitable access to evidence-based care.

We proudly support a broad range of programs that offer resources to researchers, healthcare providers, patients and their advocates, as well as our local communities. To submit a request for funding, visit our grants portal.

Listening & Learning From the Rare Disease Community

Doing right for those living with unmet needs

Learn more about our work with the rare disease community
""

Addressing occupational skin cancer risk

Millions of outdoor workers are at risk of developing non-melanoma skin cancer (NMSC), the most common type of cancer, with rates increasing annually. Globally, we support efforts to promote existing policies and create new policies to protect outdoor workers from the risk of NMSC.

Read more about how we’re taking action